Inhibition of anti-apoptotic BCL-2 (B-cell lymphoma 2) has recently emerged as a promising
new therapeutic strategy for the treatment of a variety of human cancers, including leukemia …

The BCL2 family members play a central role in regulating programmed cell death
(apoptosis) and arbitrating the cellular fate through an accurate balance between pro …

Introduction The anti-apoptotic BCL-2 family proteins, such as BCL-2, BCL-XL, and MCL-1,
are excellent cancer therapeutic targets. The FDA approval of BCL-2 selective inhibitor …

Despite recent advances in the treatment of multiple myeloma (MM), including proteasome
inhibitors and immunomodulatory agents, patients invariably relapse and alternative …

The dynamic interplay between pro-death and pro-survival Bcl-2 family proteins is
responsible for a cell's fate. Due to the recognized relevance of this family in cancer …

B-cell lymphoma 6 (BCL6) inhibition is a promising mechanism for treating hematological
cancers but high quality chemical probes are necessary to evaluate its therapeutic potential …

Resistance to standard chemotherapy agents remains a major obstacle for improving
treatment outcomes for acute myeloid leukemia (AML). The Bcl-2-selective inhibitor ABT-199 …

Targeted therapies are frequently combined with standard cytotoxic drugs to enhance
clinical response. Targeting the B-cell lymphoma 2 (BCL-2) family of proteins is an attractive …

Disruption of the physiologic balance between cell proliferation and cell death is an
important step of cancer development. Increased resistance to apoptosis is a key oncogenic …

BCL2 blunts activation of the mitochondrial pathway to apoptosis, and high-level expression
is required for chronic lymphocytic leukemia (CLL) survival. Venetoclax (ABT-199) is a small …